Anzeige
Mehr »
Login
Samstag, 02.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Technischer Ausbruch: Diese Kupferaktie ist in den letzten 52 Wochen um 300 % gestiegen! Der Durchbruch läuft!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2H7XD | ISIN: US8106481059 | Ticker-Symbol: 2SX
Tradegate
31.10.24
17:42 Uhr
3,900 Euro
+0,140
+3,72 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
SCPHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,6803,80013:05
3,6003,90001.11.

Aktuelle News zur SCPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.10.TD Cowen reiterates Buy rating on scPharmaceuticals stock, highlights optimism for Furoscix approval4
23.10.TD Cowen bekräftigt Kaufempfehlung für scPharmaceuticals-Aktie und betont Optimismus für Furoscix-Zulassung 4
15.10.scPharmaceuticals, Inc.: scPharmaceuticals to Host Key Opinion Leader (KOL) Webinar on October 22, 20244
15.08.OrbiMed Advisors LLC buys $2 million in scPharmaceuticals stock11
15.08.Earnings call: scPharmaceuticals reports growth and label expansion3
15.08.scPharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary-
14.08.scPharmaceuticals GAAP EPS of -$0.44 misses by $0.02, revenue of $8.05M beats by $0.08M1
14.08.scPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update104Generated 2Q 2024 net FUROSCIX® revenue of $8.1 million, up 33% sequentially from Q1 Completed financing that extends our cash runway through expected profitability Advanced multiple FUROSCIX growth...
► Artikel lesen
13.08.TD Cowen maintains Buy rating on scPharmaceuticals with steady price target15
12.08.scPharmaceuticals announces non-dilutive financing up to $125M with Perceptive Advisors1
12.08.scPharmaceuticals sets share price in $50 million offering1
12.08.Heart Failure-Focused scPharmaceuticals Secures FDA Approval For Expanded Use Of Furoscix, Receives Funding To Expand Commercialization2
12.08.scPharmaceuticals reports success in SCP-111 autoinjector study1
12.08.scPharmaceuticals announces public stock offering1
12.08.scPharmaceuticals gets %125M funding from Perceptive Advisors1
12.08.scPharmaceuticals secures $125 million in financing6
12.08.ScPharmaceuticals Announces Proposed Underwritten Public Offering1
12.08.ScPharma's FUROSCIX Expanded Indication In Heart Failure Gets FDA Approval; Stock Down In Pre-market1
12.08.scPharmaceuticals, Inc.: scPharmaceuticals Announces Non-Dilutive Financings Totaling Up to $125 Million with Perceptive Advisors771scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additional $50 million The term loan refinances existing debt principal; lowers...
► Artikel lesen
12.08.scPharmaceuticals Inc. - 8-K, Current Report3
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1